Physician profile
Gregory S Pokrywka
NPI 1417082322
$377,181.85
in general payments reported to CMS, 2019-2025
40 companies · $9,994 in 2025
The $9,994 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163K · 2020: $63K · 2021: $46K · 2022: $33K · 2023: $35K · 2024: $28K · 2025: $9,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Travel and Lodging: $7,817 · Consulting Fee: $7,428 · Food and Beverage: $6,425 · Honoraria: $300 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,760.00 |
| Travel and Lodging | $7,816.94 |
| Consulting Fee | $7,427.50 |
| Food and Beverage | $6,425.32 |
| Honoraria | $300.00 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $183,820.69 | 2019-2024 | |
| Amgen INC. | $83,819.15 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $51,293.21 | 2020-2025 | Nexletol, Nexlizet |
| Amryt Pharma Holdings Ltd | $14,537.13 | 2021-2023 | Juxtapid |
| Regeneron Healthcare Solutions, INC. | $11,636.14 | 2019-2025 | Evkeeza |
| Medicure Pharma INC. | $10,158.85 | 2019-2025 | Zypitamag |
| Sanofi-Aventis U.S. LLC | $6,610.59 | 2019 | |
| Merck Sharp & Dohme LLC | $6,417.10 | 2021-2024 | |
| Argenx US, INC. | $2,250.00 | 2025 | Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $1,749.71 | 2020-2025 | Leqvio |
| Lilly USA, LLC | $939.07 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $669.33 | 2019-2025 | Ozempic, Rybelsus |
| Chiesi USA, INC. | $323.06 | 2024-2025 | Juxtapid |
| Orexo US, INC. | $308.34 | 2019-2025 | Zubsolv |
| Kowa Pharmaceuticals America, INC. | $297.05 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $295.25 | 2019-2025 | Farxiga |
| Madrigal Pharmaceuticals | $281.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Alkermes, INC. | $272.30 | 2019-2023 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.35 | 2021-2024 | Tradjenta, Glyxambi, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $184.84 | 2022-2023 | |
| Regeneron Pharmaceuticals, INC. | $182.00 | 2023-2025 | Evkeeza |
| Kaneka Medical America LLC | $165.33 | 2019 | |
| Uswm, LLC | $98.82 | 2022-2023 | Lucemyra, Zimhi |
| Mdd US Operations, LLC | $82.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $81.12 | 2019 | |
| Acerus Pharmaceuticals Corporation | $72.72 | 2021-2022 | |
| Abbvie INC. | $64.62 | 2021 | |
| Abbott Laboratories | $55.38 | 2021-2023 | Freestyle Libre 3 |
| Travere Therapeutics, INC. | $43.38 | 2019-2023 | Cholbam |
| Indivior INC. | $38.89 | 2023-2024 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $26.53 | 2021 | |
| Antares Pharma, INC. | $22.69 | 2025 | Xyosted |
| Vivus LLC | $22.21 | 2023 | Pancreaze |
| Corcept Therapeutics | $19.23 | 2022 | |
| Exact Sciences Corporation | $18.94 | 2025 | Cologuard Collection Kit |
| Cleerly, INC. | $16.79 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Aegerion Pharmaceuticals, INC. | $16.16 | 2019 | |
| Allergan, INC. | $15.85 | 2020 | |
| Horizon Therapeutics Plc | $13.88 | 2023 | Krystexxa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pokrywka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.